Natera, Inc. (NASDAQ:NTRA) Given Average Recommendation of “Moderate Buy” by Analysts

Natera, Inc. (NASDAQ:NTRA) has received an average recommendation of “Moderate Buy” from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $260.3333.

NTRA has been the topic of several research reports. JPMorgan Chase & Co. upped their target price on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. BTIG Research set a $275.00 price target on Natera and gave the stock a “buy” rating in a report on Wednesday, June 24th. Wells Fargo & Company boosted their price target on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Robert W. Baird set a $265.00 price target on Natera in a research note on Friday, May 8th. Finally, Sanford C. Bernstein assumed coverage on Natera in a report on Friday, June 26th. They issued an “outperform” rating and a $310.00 price objective on the stock.

Insider Buying and Selling

In other news, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the sale, the director owned 6,183 shares of the company’s stock, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Herm Rosenman sold 16,530 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the transaction, the director owned 4,250 shares in the company, valued at $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 175,872 shares of company stock valued at $38,808,996 in the last 90 days. 5.05% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Roxbury Financial LLC increased its holdings in shares of Natera by 458.2% during the second quarter. Roxbury Financial LLC now owns 5,024 shares of the medical research company’s stock worth $1,364,000 after purchasing an additional 4,124 shares during the period. NewEdge Advisors LLC boosted its stake in shares of Natera by 3.4% in the first quarter. NewEdge Advisors LLC now owns 5,452 shares of the medical research company’s stock valued at $1,090,000 after buying an additional 179 shares during the period. Groupama Asset Managment boosted its stake in shares of Natera by 3.0% in the first quarter. Groupama Asset Managment now owns 95,061 shares of the medical research company’s stock valued at $19,011,000 after buying an additional 2,805 shares during the period. Oddo BHF Asset Management Sas acquired a new stake in Natera during the first quarter worth approximately $6,410,000. Finally, Bull Harbor Capital LLC acquired a new stake in Natera during the first quarter worth approximately $1,543,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Up 1.8%

Natera stock opened at $276.27 on Thursday. The company’s 50-day moving average price is $216.89 and its two-hundred day moving average price is $216.55. The stock has a market cap of $39.56 billion, a P/E ratio of -169.49 and a beta of 1.51. Natera has a twelve month low of $131.81 and a twelve month high of $279.42.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.